Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study

Fig. 2

Results for stratified analyses of PS-matched HRs (95% CIs) for adverse respiratory events† associated with the use of SGLT2is versus DPP4is. †Defined as a composite end point of acute pulmonary edema, acute respiratory distress syndrome, pneumonia, or respiratory failure. *Prescription for insulin in past year. CI, confidence interval; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DPP4i, dipeptidyl peptidase-4 inhibitor; HR, hazard ratio; PS, propensity score; SGLT2i, sodium-glucose cotransporter 2 inhibitor

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us